10257-99-5

Upstream product

• 6622-54-4 N-(β-carboxyethyl)carbazole 
• 7664-39-3 hydrogen fluoride 
• 2680-03-7 N,N-Dimethylacrylamide 
• 86-74-8 9H-carbazole 
• 5337-01-9 N-(2-cyanoethyl)carbazole 

Downstream Products

• 116605-12-0 5-benzyl-pyrido[3,2,1-jk]carbazol-4-one 
• 116570-65-1 5-benzylidene-5,6-dihydro-pyrido[3,2,1-jk]carbazol-4-one 
• 123965-15-1 5-(4-diethylamino-benzylidene)-5,6-dihydro-pyrido[3,2,1-jk]carbazol-4-one 
• 114947-41-0 5-(4-dimethylamino-phenylimino)-5,6-dihydro-pyrido[3,2,1-jk]carbazol-4-one 
• 123965-16-2 5-(4-diethylamino-benzyl)-pyrido[3,2,1-jk]carbazol-4-one 
• 226562-63-6 5,6-dihydro-5-phenoxy-4H-pyrido[3,2,1-jk]carbazole-4-one 

Relevant academic research and scientific papers

New approach to the synthesis of 1,2,3,4-tetrahydroquinolin-4-ones

The reaction of aromatic amines with complexes of N,N-dimethylacrylamide and N,N-dimethylmethacrylamide with trifluoromethanesulfonic anhydride leads to the formation of tetrahydro-4-quinolones and 3-methyltetrahydro-4-quinolones respectively. 1997 Plenum Publishing Corporation.

Pyridocarbazole derivatives having cGMP-PDE inhibitory activity

PCT No. PCT/JP97/01829 Sec. 371 Date Jan. 29, 1998 Sec. 102(e) Date Jan. 29, 1998 PCT Filed May 29, 1997 PCT Pub. No. WO97/45427 PCT Pub. Date Dec. 4, 1997The invention relates to novel pyridocarbazole derivatives having highly selective action in inhibiting cyclic GMP-phosphodiesterase (hereinafter abbreviated as cGMP-PDE), processes for producing such derivatives, agents containing at least one of such derivatives as an active ingredient for preventing and/or treating pulmonary hypertension, ischemic heart diseases or diseases against which the cGMP-PDE inhibitory action is effective, and intermediates useful for the production of pyridocarbazole derivatives.